FindTrial
Sign In

A Phase III Study of IPD-1151T in Patients With Interstitial Cystitis

A Phase III Study of IPD-1151T in Patients With Interstitial Cystitis

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220253
Enrollment
Unknown
Registered
2006-06-08
Start date
2006-06-08
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Interstitial cystitis

Interventions

investigational material(s) Generic name etc : IPD-1151T INN of investigational material : suplatast tosilate Therapeutic category code : 259 Other agents for uro-genital and anal organ Dosage and Ad

Sponsors

Taiho Pharmaceutical Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1)20 years and older 2)Interstitial cystitis-characteristic findings observed by cystoscope under hydrodistension 3)Stable for 12 weeks and more following hydrodistension of the bladder 4)IC symptom score of 7 and higher at the end of 2-week observation period 5)Pain score including bladder pain of 4 and higher

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Improvement of IC symptom score and incidence of adverse drug reactions—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026